It has also been suggested that this loss of FGFR3 mutation during tumor progression may potentially alleviate oncogene-induced upregulation of p16 and related cell cycle checkpoint genes allowing tumor progression [72]. The gene discussed is FGFR3; the disease is neoplasm.